Mar 07, 2019 / 09:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Fourth Quarter and 2018 Year-End Conference Call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to turn the call over to Ms. Pam Murphy. Ma'am, you may begin.
Pam Murphy -
Thank you. Good afternoon, and thank you all for joining us. On the call today from the Arbutus management team are Dr. Mark Murray, CEO; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and Dave Hastings, Chief Financial Officer.
Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline, including clinical time lines and results for the lead compounds AB-506, AB-729, and AB-452; our expected cash runway and expected revenues from our current and potential licensing agreements. These forward-looking statements are subject to a number of risks and uncertainties that may cause our
Q4 2018 Arbutus Biopharma Corp Earnings Call Transcript
Mar 08, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers